<div id="readability-page-1"><div>Esperion Therapeutics Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. &gt;&gt;&gt;CLICK HERE To Learn More. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-espr/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MDQ5NjUxNTByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MDQ5NjUxNTByMQ"/> Kahn Swick &amp; Foti, LLC Managing Partner Lewis S. Kahn lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20260504965150/en/</div></div>

ESPR

Kahn Swick & Foti, LLC 正在調查 Esperion Therapeutics, Inc.（納斯達克代碼：ESPR）擬售給 ARCHIMED 基金的事宜。股東將獲得每股 3.16 美元的現金，以及潛在的里程碑付款。該公司旨在評估這一報價是否充分反映了公司的價值及其形成過程。感興趣的各方可以聯繫 KSF 以獲取有關其在此次交易中法律權利的更多信息

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

Esperion Therapeutics 投資者警報：Kahn Swick & Foti, LLC 正在調查擬議出售 Esperion Therapeutics, Inc.的價格和流程是否合理 - ESPR